Immune Repertoire Sequencing Market Outlook:
Immune Repertoire Sequencing Market size was valued at USD 366.11 million in 2025 and is set to exceed USD 915.62 million by 2035, expanding at over 9.6% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of immune repertoire sequencing is estimated at USD 397.74 million.
The market is primarily driven by the escalating government encouragement for pharmacogenomics-based drug recovery. Furthermore, growth in multiple therapeutic areas such as cardiology, pain management, oncology, infectious diseases, and others is estimated to boost the market expansion in the projected period.
Additionally, the industry has been driven by many organizations seeking answers to biomarkers of the immune system. Mergers and acquisitions are also driving the market. More collaboration, acquisition, and agreement among the market players are majorly contributing to the industry growth. In order to produce effective and creative immunotherapies ArcherDX and Ambry Genetics joined hands in March 2018.
